IL244421A0 - Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy - Google Patents

Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy

Info

Publication number
IL244421A0
IL244421A0 IL244421A IL24442116A IL244421A0 IL 244421 A0 IL244421 A0 IL 244421A0 IL 244421 A IL244421 A IL 244421A IL 24442116 A IL24442116 A IL 24442116A IL 244421 A0 IL244421 A0 IL 244421A0
Authority
IL
Israel
Prior art keywords
kits
methods
breast cancer
radiation therapy
treating breast
Prior art date
Application number
IL244421A
Other languages
English (en)
Hebrew (he)
Original Assignee
British Columbia Cancer Agency
Univ Washington
Univ Utah Res Found
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency, Univ Washington, Univ Utah Res Found, Univ North Carolina filed Critical British Columbia Cancer Agency
Publication of IL244421A0 publication Critical patent/IL244421A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL244421A 2013-09-09 2016-03-03 Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy IL244421A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875373P 2013-09-09 2013-09-09
US201461990948P 2014-05-09 2014-05-09
PCT/US2014/054760 WO2015035377A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Publications (1)

Publication Number Publication Date
IL244421A0 true IL244421A0 (en) 2016-04-21

Family

ID=51688397

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244421A IL244421A0 (en) 2013-09-09 2016-03-03 Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy

Country Status (7)

Country Link
US (1) US20150072021A1 (enExample)
EP (1) EP3044332A1 (enExample)
JP (1) JP2016537010A (enExample)
AU (1) AU2014317843A1 (enExample)
CA (1) CA2923166A1 (enExample)
IL (1) IL244421A0 (enExample)
WO (1) WO2015035377A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
WO2016085841A1 (en) 2014-11-24 2016-06-02 Nanostring Technologies, Inc. Methods and apparatuses for gene purification and imaging
AU2015359479A1 (en) * 2014-12-09 2017-06-15 King's College London Breast cancer treatment with taxane therapy
US11530448B2 (en) 2015-11-13 2022-12-20 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN108456730B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用
EP3946383A4 (en) * 2019-04-04 2023-05-03 University of Utah Research Foundation MULTIGENE TEST TO EVALUATE THE RISK OF CANCER RECURRENCE
KR102414754B1 (ko) * 2019-10-10 2022-06-30 주식회사 종근당 직장암 항암화학방사선 치료 반응 예측용 바이오마커
TW202129008A (zh) * 2019-11-05 2021-08-01 香港商行動基因（智財）有限公司 檢測異檸檬酸脫氫酶突變的套組及方法
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
KR20240081508A (ko) 2022-11-17 2024-06-10 인제대학교 산학협력단 Dna 메틸화 변화를 통한 방사선치료 반응성 예측용 바이오마커 조성물 및 이의 용도
CN116622885B (zh) * 2023-05-23 2025-01-10 福建省农业科学院果树研究所 一种用于不同桃花色鉴定的分子标记方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
JP5537034B2 (ja) 2005-12-23 2014-07-02 ナノストリング テクノロジーズ，インコーポレーテッド ナノレポーターならびにその作製方法および使用方法
US8986926B2 (en) 2005-12-23 2015-03-24 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
US7892740B2 (en) * 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2008124847A2 (en) 2007-04-10 2008-10-16 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2009108215A1 (en) * 2007-09-06 2009-09-03 Aviaradx, Inc. Tumor grading and cancer prognosis
EP2195005B1 (en) * 2007-09-14 2015-05-27 University of South Florida Gene signature for the prediction of radiation therapy response
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
CA2857505A1 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2013177245A2 (en) * 2012-05-22 2013-11-28 Nanostring Technologies, Inc. Nano46 genes and methods to predict breast cancer outcome

Also Published As

Publication number Publication date
EP3044332A1 (en) 2016-07-20
CA2923166A1 (en) 2015-03-12
AU2014317843A1 (en) 2016-03-24
WO2015035377A1 (en) 2015-03-12
JP2016537010A (ja) 2016-12-01
US20150072021A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
IL244421A0 (en) Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy
IL272206A (en) Combined treatment for cancer
IL245731A0 (en) Combined treatment for cancer
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
IL236336A0 (en) Methods of treating breast cancer with gemcitabine therapy
ZA201506877B (en) Methods of treating bladder cancer
PL3033086T3 (pl) Terapia skojarzona do leczenia nowotworów złośliwych
IL248487A0 (en) Methods for treating early breast cancer with trastuzumab-dmi-mcc and pertuzumab
IL240935A0 (en) Methods of treating lung cancer
EP2967503A4 (en) Systems and methods for treating prostate cancer
IL244884B (en) Antibodies conjugated against ly75 for cancer therapy
PT3490560T (pt) Niraparib para utilização num método de tratamento de cancro da próstata
SG11201508878WA (en) Methods of treating cancer
IL244353A0 (en) Compounds and use for cancer treatment
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
PL2976645T3 (pl) Wsparcie decyzji klinicznej (cds) dla radioterapii raka prostaty
PL3016682T3 (pl) Sposoby leczenia nowotworu
ZA201507762B (en) Methods of treating cancer
IL239031A0 (en) Combined therapy for the treatment of her2-positive cancers
EP2932273A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
PL3010508T3 (pl) Skojarzenie RO5503781, kapecytabiny i oksaliplatyny do leczenia raka
HK1226447A1 (en) Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
GB201610362D0 (en) Predicting responsiveness to therapy in prostate cancer
GB201700776D0 (en) Predicting responsiveness to therapy in prostate cancer
PL3010513T3 (pl) Skojarzenie RO5503781 i kapecytabiny do leczenia raka